A dengue vaccine whirlwind update
Dengue virus (DENV) is a mosquito-borne single-stranded RNA virus of the Flaviviridae family with four serotypes (DENV1, DENV2, DENV3, and DENV4) circulating many tropical and subtropical regions of the world. Endemic in more than 100 countries, DENV results in over 400 million cases annually, a sub...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-04-01
|
| Series: | Therapeutic Advances in Infectious Disease |
| Online Access: | https://doi.org/10.1177/20499361231167274 |
| _version_ | 1827962949536317440 |
|---|---|
| author | Ruwandi Kariyawasam Mark Lachman Saniya Mansuri Sumontra Chakrabarti Andrea K. Boggild |
| author_facet | Ruwandi Kariyawasam Mark Lachman Saniya Mansuri Sumontra Chakrabarti Andrea K. Boggild |
| author_sort | Ruwandi Kariyawasam |
| collection | DOAJ |
| description | Dengue virus (DENV) is a mosquito-borne single-stranded RNA virus of the Flaviviridae family with four serotypes (DENV1, DENV2, DENV3, and DENV4) circulating many tropical and subtropical regions of the world. Endemic in more than 100 countries, DENV results in over 400 million cases annually, a subset presenting with severe or life-threatening illnesses such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). While no specific treatments outside of supportive management exist, vaccines are an area of major research with two vaccines, Dengvaxia ® (CYD-TDV) and Denvax ® (TAK003), recently licensed for clinical use. CYD-TDV is highly efficacious in children 9 years or older who have had prior DENV infection due to the high risk of severe disease in seronegative children aged 2–5 years. Meanwhile, TAK003 has shown efficacy at 97.7% and 73.7% against, DENV2 and DENV1, respectively, in phase 3 clinical trials across Latin America and Asia in healthy children aged 4–16 with virologically confirmed dengue. Other vaccines including TV003 and TV005 continue to be developed across the world, with the hopes of entering clinical trials in the near future. We discuss the current state of vaccine development against dengue, with a focus on CYD-TDV and TAK003 as promising novel vaccines to target this neglected tropical disease (NTD). |
| first_indexed | 2024-04-09T16:50:35Z |
| format | Article |
| id | doaj.art-cf38bd8d5fa64baf8121c5ba3c62cbdf |
| institution | Directory Open Access Journal |
| issn | 2049-937X |
| language | English |
| last_indexed | 2024-04-09T16:50:35Z |
| publishDate | 2023-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Infectious Disease |
| spelling | doaj.art-cf38bd8d5fa64baf8121c5ba3c62cbdf2023-04-21T14:03:29ZengSAGE PublishingTherapeutic Advances in Infectious Disease2049-937X2023-04-011010.1177/20499361231167274A dengue vaccine whirlwind updateRuwandi KariyawasamMark LachmanSaniya MansuriSumontra ChakrabartiAndrea K. BoggildDengue virus (DENV) is a mosquito-borne single-stranded RNA virus of the Flaviviridae family with four serotypes (DENV1, DENV2, DENV3, and DENV4) circulating many tropical and subtropical regions of the world. Endemic in more than 100 countries, DENV results in over 400 million cases annually, a subset presenting with severe or life-threatening illnesses such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). While no specific treatments outside of supportive management exist, vaccines are an area of major research with two vaccines, Dengvaxia ® (CYD-TDV) and Denvax ® (TAK003), recently licensed for clinical use. CYD-TDV is highly efficacious in children 9 years or older who have had prior DENV infection due to the high risk of severe disease in seronegative children aged 2–5 years. Meanwhile, TAK003 has shown efficacy at 97.7% and 73.7% against, DENV2 and DENV1, respectively, in phase 3 clinical trials across Latin America and Asia in healthy children aged 4–16 with virologically confirmed dengue. Other vaccines including TV003 and TV005 continue to be developed across the world, with the hopes of entering clinical trials in the near future. We discuss the current state of vaccine development against dengue, with a focus on CYD-TDV and TAK003 as promising novel vaccines to target this neglected tropical disease (NTD).https://doi.org/10.1177/20499361231167274 |
| spellingShingle | Ruwandi Kariyawasam Mark Lachman Saniya Mansuri Sumontra Chakrabarti Andrea K. Boggild A dengue vaccine whirlwind update Therapeutic Advances in Infectious Disease |
| title | A dengue vaccine whirlwind update |
| title_full | A dengue vaccine whirlwind update |
| title_fullStr | A dengue vaccine whirlwind update |
| title_full_unstemmed | A dengue vaccine whirlwind update |
| title_short | A dengue vaccine whirlwind update |
| title_sort | dengue vaccine whirlwind update |
| url | https://doi.org/10.1177/20499361231167274 |
| work_keys_str_mv | AT ruwandikariyawasam adenguevaccinewhirlwindupdate AT marklachman adenguevaccinewhirlwindupdate AT saniyamansuri adenguevaccinewhirlwindupdate AT sumontrachakrabarti adenguevaccinewhirlwindupdate AT andreakboggild adenguevaccinewhirlwindupdate AT ruwandikariyawasam denguevaccinewhirlwindupdate AT marklachman denguevaccinewhirlwindupdate AT saniyamansuri denguevaccinewhirlwindupdate AT sumontrachakrabarti denguevaccinewhirlwindupdate AT andreakboggild denguevaccinewhirlwindupdate |